MYP_171141
Basic Information
Idarucizumab
Hemostasis Anticoagulant activity
Standard
225 amino acids
C1065H1645N271O334S5
Standard
Sequence
QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYIVDWIRQPPGKGLEWIGVIWAGGSTGYNSALRSRVSITKDTSKNQFSLKLSSVTAADTAVYYCASAAYYSYYNYDGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC
Physicochemical Analysis
23749.39 Da
8.89
4.88
4.45
0.0217
-0.05
0.62
0.14
36.26
76.62
0.1067
46870.00
47120.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0140565 VERIFIED: NO
Provenance & Taxonomy
Cricetulus griseus [Animal]
Monoclonal antibody
10029
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Disulfide-bonded therapeutic scaffold described in source text
Bio-Activity Profile
Coagulation factor replacement Anticoagulant
CHO
initial half-life: 47 minutes terminal half-life: 10.3 h